Market Cap ₹45 Cr.
Stock P/E
P/B 2.6
Current Price ₹71.4
Book Value ₹ 27.7
Face Value 10
52W High ₹101.6
Dividend Yield 0%
52W Low ₹ 37
Vanta Bioscience Limited is an primarily India based preclinical contract studies enterprise. The Company is focused on providing a host of preclinical safety assessment services for clients from pharmaceutical, medical devices, nutraceuticals, feed additive, biotech, agrochemicals, cosmetics, and chemical industries. In addition, the Company additionally provides risk evaluation services for evaluating the safety of the active pharmaceutical substances (API), excipients, extractable and leachables which includes pharmaceutical impurities resulting because of manufacturing system or due to degradation of the product. The Company also gives services for dedication of health based exposure limits for PDE, or ADE including OEL for pharmaceutical producers.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 12 | 14 | 10 | 10 | 6 | |
| Other Income | 0 | 0 | 0 | 0 | 1 | |
| Total Income | 12 | 14 | 10 | 10 | 7 | |
| Total Expenditure | 9 | 9 | 6 | 6 | 9 | |
| Operating Profit | 4 | 4 | 4 | 4 | -2 | |
| Interest | 2 | 2 | 2 | 2 | 6 | |
| Depreciation | 1 | 1 | 1 | 1 | 3 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 1 | 1 | 1 | 0 | -10 | |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | |
| Profit After Tax | 1 | 1 | 0 | 0 | -10 | |
| Adjustments | -0 | -0 | 0 | -0 | 4 | |
| Profit After Adjustments | 1 | 1 | 0 | 0 | -6 | |
| Adjusted Earnings Per Share | 1.1 | 1.6 | 0.7 | 0.1 | -10.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -40% | -25% | 0% | 0% |
| Operating Profit CAGR | -150% | NAN% | 0% | 0% |
| PAT CAGR | 0% | NAN% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 37% | -24% | -16% | NA% |
| ROE Average | -50% | -16% | -8% | -8% |
| ROCE Average | -6% | 1% | 4% | 4% |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Shareholder's Funds | 22 | 23 | 24 | 24 | 18 |
| Minority's Interest | 1 | 1 | 2 | 5 | 1 |
| Borrowings | 12 | 14 | 28 | 37 | 47 |
| Other Non-Current Liabilities | 0 | 1 | 1 | 1 | 1 |
| Total Current Liabilities | 3 | 10 | 15 | 14 | 18 |
| Total Liabilities | 39 | 49 | 70 | 81 | 85 |
| Fixed Assets | 18 | 21 | 29 | 36 | 57 |
| Other Non-Current Assets | 4 | 8 | 20 | 31 | 12 |
| Total Current Assets | 17 | 20 | 20 | 15 | 15 |
| Total Assets | 39 | 49 | 70 | 81 | 85 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 3 | 0 | 3 | 0 |
| Cash Flow from Operating Activities | -1 | 2 | 7 | 5 | -1 |
| Cash Flow from Investing Activities | -5 | -7 | -22 | -17 | -6 |
| Cash Flow from Financing Activities | 10 | 2 | 18 | 9 | 6 |
| Net Cash Inflow / Outflow | 3 | -3 | 2 | -2 | -0 |
| Closing Cash & Cash Equivalent | 3 | 0 | 3 | 0 | 0 |
| # | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 1.1 | 1.59 | 0.71 | 0.14 | -10.27 |
| CEPS(Rs) | 2.23 | 3.49 | 2.69 | 2.3 | -12.32 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 35.25 | 37.18 | 37.89 | 38.03 | 27.75 |
| Core EBITDA Margin(%) | 26.35 | 30.89 | 39.31 | 35.8 | -38.14 |
| EBIT Margin(%) | 22.47 | 23.26 | 27.18 | 26.58 | -69.74 |
| Pre Tax Margin(%) | 8.88 | 9.49 | 5.87 | 2.36 | -163.53 |
| PAT Margin (%) | 5.62 | 7.16 | 4.47 | 1.39 | -166.43 |
| Cash Profit Margin (%) | 11.34 | 15.57 | 16.93 | 14.98 | -123.88 |
| ROA(%) | 1.78 | 2.31 | 0.76 | 0.18 | -12.57 |
| ROE(%) | 3.14 | 4.43 | 1.89 | 0.56 | -50.31 |
| ROCE(%) | 7.87 | 8.62 | 5.42 | 4 | -6.1 |
| Receivable days | 45.95 | 38.14 | 61.93 | 59.32 | 89.94 |
| Inventory Days | 271.56 | 300.03 | 432.17 | 320.25 | 418.55 |
| Payable days | 126.64 | 146.72 | 213.02 | 761.36 | 1287 |
| PER(x) | 138.62 | 57.18 | 228.87 | 786.33 | 0 |
| Price/Book(x) | 4.34 | 2.45 | 4.3 | 2.89 | 2.07 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 8.82 | 5.42 | 13.88 | 11.77 | 14.88 |
| EV/Core EBITDA(x) | 30.41 | 16.66 | 34.22 | 29.29 | -54.7 |
| Net Sales Growth(%) | 0 | 13.85 | -28.63 | -1.3 | -35.22 |
| EBIT Growth(%) | 0 | 17.85 | -17.06 | -5.62 | -269.96 |
| PAT Growth(%) | 0 | 45.14 | -55.73 | -69.96 | -7855.72 |
| EPS Growth(%) | 0 | 44.23 | -55.25 | -80.38 | -7449.46 |
| Debt/Equity(x) | 0.6 | 0.74 | 1.5 | 1.87 | 3.26 |
| Current Ratio(x) | 5.17 | 1.99 | 1.34 | 1.02 | 0.86 |
| Quick Ratio(x) | 2.39 | 0.6 | 0.69 | 0.51 | 0.46 |
| Interest Cover(x) | 1.65 | 1.69 | 1.28 | 1.1 | -0.74 |
| Total Debt/Mcap(x) | 0.14 | 0.3 | 0.35 | 0.65 | 1.57 |
| # | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 69.93 | 69.93 | 69.93 | 69.11 | 69 | 69 | 69.36 | 69.36 | 69.36 | 69.36 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 30.07 | 30.07 | 30.07 | 30.89 | 31 | 31 | 30.64 | 30.64 | 30.64 | 30.64 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.19 | 0.19 | 0.19 | 0.19 | 0.2 | 0.2 | 0.19 | 0.19 | 0.19 | 0.19 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
